LEPU BIOPHARMA CO., LTD.
樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2157)

INSIDE INFORMATION ANNOUNCEMENT

EXCLUSIVE LICENSE AGREEMENT WITH ASTRAZENECA FOR CMG901

This announcement is made by Lepu Biopharma Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") is pleased to announce that KYM Biosciences Inc. ("**KYM**"), a joint venture formed by us and Keymed Biosciences Inc. ("**Keymed**"), has entered into a global exclusive out-license agreement (the "**License Agreement**") with AstraZeneca AB ("**AstraZeneca**"), a global pharmaceutical company who to the best knowledge and belief of the Company, is independent of and not connected with the Company and its connected persons (as defined in the Listing Rules), to develop and commercialize CMG901, a drug candidate co-developed by us and Keymed through KYM.

Upon the execution of the License Agreement and subject to terms and conditions thereof (including obtaining certain regulatory approval for the licensing transaction), AstraZeneca will be granted an exclusive global license for research, development, registration, manufacturing, and commercialization of CMG901, and shall be responsible for all costs and activities associated with the further development and commercialization of CMG901 in accordance with the License Agreement.

According to the License Agreement and subject to the terms and conditions thereof, KYM shall receive an upfront payment of US$63 million with the potential for additional payments up to US$1,125 million subject to achievement of certain development, regulatory and commercial milestones. In addition, KYM is entitled to receive tiered royalties on net sales from AstraZeneca. KYM is obliged to provide assistance and staff to facilitate technology and know-how transfer. Except as otherwise agreed, AstraZeneca will be responsible for bearing all costs for activities associated with the development and regulatory affairs on ongoing trial in relation to CMG901. The License Agreement is subject to customary closing conditions, including completion of antitrust regulatory reviews.

The Board believes that entering the License Agreement is in the best interests of the Company and its shareholders as a whole. The Company will leverage on this opportunity to further strengthen its strategic alliances and collaborations with its strategic partners in the development and commercialization of its drug candidates.

ABOUT CMG901

CMG901 is a Claudin 18.2-targeting anti-body drug conjugates ("**ADC**") comprising of a Claudin 18.2-specific antibody, a cleavable linker and a toxic payload, monomethyl auristatin E ("**MMAE**").

It is the first Claudin 18.2 ADC to have received investigational new drug ("**IND**") clearance both in China and the U.S. Claudin 18.2 is selectively and widely expressed in gastric cancer, pancreatic cancer and other solid tumors, which makes it an ideal tumor target for therapeutic development.

We have completed the patient enrollment of the dose-escalation stage of the Phase I clinical trial of CMG901 in subjects with solid tumors in the first half of 2022, and plan to present and disclose the data from the Phase I clinical trial in academic papers/conferences in the future. Furthermore, we also initiated the dose-expansion stage of the Phase I clinical trial of CMG901 in subjects with solid tumors in China in the second quarter of 2022 and the Phase Ia Trial data has been presented at the 2023 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology ("**2023 ASCO GI**") in January 2023.

In April 2022, CMG901 for the treatment of relapsed/refractory gastric cancer and gastroesophageal junction adenocarcinoma has been granted the Fast Track Designation by the Food and Drug Administration (the "**FDA**") of the United States. Previously, we have received the Orphan-drug Designation for this indication from the FDA.

About KYM

KYM is a joint venture formed by us and Keymed, which is held as to 30% by us and 70% by Keymed. It is primarily engaged in the development and commercialization of CMG901.

This announcement is made by the Company to provide information to the shareholders and potential investors of the Company. There is no assurance that the Company will ultimately develop, launch and/or commercialize the product successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Lepu Biopharma Co., Ltd.
Dr. Pu Zhongjie
Chairman of the Board and Executive Director

Shanghai, the PRC, February 23, 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Pu Zhongjie (Chairman), Dr. Sui Ziye (Chief Executive Officer) and Dr. Hu Chaohong (Co-Chief Executive Officer) as executive Directors; Ms. Pu Jue, Mr. Yang Hongbing and Mr. Lin Xianghong as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive directors.